英派药业将塞纳帕利海外66国商业化权益授权给Pharmanovia

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# IMPACT Therapeutics, Inc 南 京 英 派 藥 業 股 份 有 限 公 司

(A joint stock company established in the People’s Republic of China with limited liability)

(Stock Code: 7630)

VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR

SENAPARIB IN EUROPE, MIDDLE EAST AND NORTH AFRICA, AUSTRALIA AND NEW ZEALAND

This announcement is made by IMPACT Therapeutics, Inc (the “Company”, together with its subsidiaries, the “Group”) on a voluntary basis to inform the Company’s shareholders and potential investors about the latest business update of the Group.

The Company is pleased to announce that the Group has entered into an exclusive partnership (the “Exclusive Partnership”) with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pharma to bring innovative specialty medicines to patients, to grant Pharmanovia the exclusive rights to manufacture, develop and commercialise senaparib in Europe, Middle East and North Africa, Australia and New Zealand for maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer.

### KEY TRANSACTION HIGHLIGHTS

- • The Group is eligible to receive an upfront payment plus near-term regulatory milestones and commercial milestone payments upon achieving certain sales thresholds, with a total amount up to EUR423.5 million, and such further tiered royalties up to the mid-twenties (%) on product net sales;
- • The Exclusive Partnership expands senaparib’s global reach to 66 countries; and
- • Marketing Authorisation Application (MAA) of senaparib for 1L maintenance therapy for adult patients with advanced ovarian cancer in Europe was formally accepted by the European Medicines Agency (the “EMA”) in August 2025, with approval expected in the second half of 2026.


### THE EXCLUSIVE LICENSE AGREEMENT

Under the licensing agreement in relation to the Exclusive Partnership, the Group has granted exclusive manufacturing, development and commercialisation rights of senaparib for maintenance monotherapy for advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer to Pharmanovia in 66 countries, including, among others, all 27 European Union member states, as well as the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand and countries in the Middle East and North Africa.

The Group is eligible to receive consideration up to EUR423.5 million in total, comprising an upfront payment plus near-term regulatory milestones and commercial milestone payments upon achieving certain sales thresholds, and such further tiered royalties up to the mid-twenties (%) on product net sales.

The Exclusive Partnership marks the first step for the Group to bring its validated treatment options to patients outside of China, expanding senaparib’s business footprint across Europe, Middle East and North Africa as well as Australia and New Zealand. The Group will work closely with Pharmanovia to advance the commercialisation of senaparib in the collaboration territories. By leveraging Pharmanovia’s specialist expertise and established infrastructure, we expect senaparib to reach target patients in the collaboration territories more quickly following approval, helping to deliver high-quality treatment options to address unmet medical needs. This collaboration will not only enhance the brand recognition of the product and the Group on a global scale, but also further broaden the Group’s strategic layout for global commercialisation. The Group expects that this collaboration will have a positive and profound impact on its development.

### ABOUT SENAPARIB (IMP4297)

Senaparib (派舒寧®) is a novel, highly potent PARP1/2 inhibitor independently developed by the Company. Its unique molecular structure ensures excellent target selectivity and a wide safety window. Senaparib capsules received National Medical Products Administration of China (NMPA) approval in January 2025 as a first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer achieving complete or partial response to platinum-based chemotherapy, and has been subsequently included in the National Reimbursement Drug List (NRDL) in December 2025. The Company is actively advancing the clinical and regulatory development of senaparib globally. Its Marketing Authorisation Application (MAA) in Europe was formally accepted by the EMA in August 2025, with approval expected in the second half of 2026. Concurrently, the Company is pursuing life cycle management for senaparib, exploring combination therapy opportunities, and expanding into multiple indications.

### ABOUT PHARMANOVIA

Pharmanovia is a global specialty pharmaceutical company focused on innovative specialty medicines and trusted established brands. Pharmanovia combines scientific, medical, regulatory, market access, supply chain and commercial expertise to bring medicines to patients. Together, they reflect a business built to meet patient needs today while helping shape better outcomes for tomorrow.

### LISTING RULES IMPLICATIONS

To the best knowledge, information and belief of the Company, having made all reasonable enquiries, Pharmanovia and its ultimate beneficial owners are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”)). The transactions contemplated under the Exclusive Partnership are transactions of a revenue nature carried out in the ordinary and usual course of business of the Company and do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that senaparib will be successfully developed or ultimately marketed in the licensed territories. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board IMPACT Therapeutics, Inc 南京英派藥業股份有限公司 Dr. Sui Xiong CAI

## Executive Director and Chief Executive Officer

Hong Kong, July 30, 2026

## As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.